GT Biopharma Ownership | Who Owns GT Biopharma?


OverviewForecastFinancialsChart

GT Biopharma Ownership Summary


GT Biopharma is owned by 13.50% institutional investors, 20.50% insiders, and 66.00% retail investors. Drw securities is the largest institutional shareholder, holding 5.14% of GTBP shares. Fidelity Extended Market Index is the top mutual fund, with 0.36% of its assets in GT Biopharma shares.

GTBP Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockGT Biopharma13.50%20.50%66.00%
SectorHealthcare Stocks 42.64%10.86%46.50%
IndustryBiotech Stocks 45.45%10.77%43.78%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Drw securities142.38K5.14%$83.50K
Bank of montreal /can/92.53K3.34%$54.59K
Seacrest wealth management50.00K1.27%$36.62K
Geode capital management23.97K0.86%$14.25K
Two sigma securities17.07K0.62%$10.01K
Morgan stanley14.02K0.51%$8.22K
Coston, mcisaac & partners17.09K0.43%$13.00K
Am investment strategies15.00K0.38%$12.00K
Wells fargo & company/mn10.01K0.36%$5.87K
Blackrock funding, inc. /de9.74K0.35%$5.71K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Seacrest wealth management50.00K0.00%$36.62K
Coston, mcisaac & partners17.09K0.00%$13.00K
Am investment strategies15.00K0.00%$12.00K
Wolff wiese magana5.00K0.00%$3.93K
Drw securities142.38K0.00%$83.50K
Two sigma securities17.07K0.00%$10.01K
Verdence capital advisors13.00K0.00%$10.21K
Newbridge financial services group3.75K0.00%$2.94K
Parsons capital management inc/ri10.90K0.00%$8.56K
Tower research capital llc (trc)1.70K-$999.00

Top Buyers

HolderShares% AssetsChange
Drw securities142.38K0.00%142.38K
Seacrest wealth management50.00K0.00%50.00K
Coston, mcisaac & partners17.09K0.00%17.09K
Two sigma securities17.07K0.00%17.07K
Am investment strategies15.00K0.00%15.00K

Top Sellers

HolderShares% AssetsChange
Renaissance---26.30K
Vanguard group---10.50K
Advisor group5.07K--6.38K
Ubs group1.00--2.63K
Mount yale investment advisors---46.00

New Positions

HolderShares% AssetsChangeValue
Drw securities142.38K0.00%142.38K$83.50K
Seacrest wealth management50.00K0.00%50.00K$36.62K
Coston, mcisaac & partners17.09K0.00%17.09K$13.00K
Two sigma securities17.07K0.00%17.07K$10.01K
Am investment strategies15.00K0.00%15.00K$12.00K

Sold Out

HolderChange
Front row advisors-1.00
Ghp investment advisors-33.00
Mount yale investment advisors-46.00
Vanguard group-10.50K
Renaissance-26.30K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202520-374,21692.24%1319.59%7-36.36%433.33%
Jun 30, 2025215.00%189,92690.52%844.82%11120.00%3-40.00%
Mar 31, 20252011.11%99,688-91.98%40.10%5-28.57%5150.00%
Dec 31, 20241820.00%1,242,247-0.30%652.11%7133.33%2-33.33%
Sep 30, 202415-6.25%1,246,00715.35%551.40%3-25.00%3-50.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Fidelity Extended Market Index12.72K0.36%-90.00
Vanguard Institutional Extnd Mkt Idx Tr7.22K0.22%-3.29K
Spartan Extended Market Index Pool E4.50K0.20%4.26K
Spartan Extended Market Index Pool F4.71K0.13%90.00
Fidelity Series Total Market Index3.79K0.11%-
Dimensional US Core Equity USD Acc2.20K0.10%-
Fidelity Total Market Index2.20K0.06%-
BlackRock Extended Equity Market K1.16K0.05%-
Dimensional US Sustainability Core 1 ETF1.64K0.05%-
DFA US Sustainability Core 1799.000.04%-

Recent Insider Transactions


DateNameRoleActivityValue
Apr 11, 2023Breen Michael Martin Executive Chairman/Interim CEOBuy$25.00K
Apr 06, 2023Ohri Manu CFO & SecretaryBuy$25.00K
Dec 22, 2020Wendel Bruce-Buy$12.19K
Nov 16, 2020Wendel Bruce-Buy$10.26K
Dec 22, 2020Wendel Bruce-Buy$3.85K

Insider Transactions Trends


DateBuySell
2023 Q22-
2023 Q1--
2022 Q3--
2022 Q2--
2022 Q1--

GTBP Ownership FAQ


Who Owns GT Biopharma?

GT Biopharma shareholders are primarily institutional investors at 13.50%, followed by 20.50% insiders and 66.00% retail investors. The average institutional ownership in GT Biopharma's industry, Biotech Stocks , is 45.45%, which GT Biopharma falls below.

Who owns the most shares of GT Biopharma?

GT Biopharma’s largest shareholders are Drw securities (142.38K shares, 5.14%), Bank of montreal /can/ (92.53K shares, 3.34%), and Seacrest wealth management (50K shares, 1.27%). Together, they hold 9.74% of GT Biopharma’s total shares outstanding.

Does Blackrock own GT Biopharma?

BlackRock is not among the top 10 institutional shareholders of GT Biopharma.

Who is GT Biopharma’s biggest shareholder by percentage of total assets invested?

Seacrest wealth management is GT Biopharma’s biggest shareholder by percentage of total assets invested, with 0.00% of its assets in 50K GT Biopharma shares, valued at 36.62K$.

Who is the top mutual fund holder of GT Biopharma shares?

Fidelity Extended Market Index is the top mutual fund holder of GT Biopharma shares, with 0.36% of its total shares outstanding invested in 12.72K GT Biopharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools